Literature DB >> 12423251

Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis.

Patrice Delobel1, Stéphane Flament, Malika Hamdane, Christel Mailliot, Anne-Véronique Sambo, Séverine Bégard, Nicolas Sergeant, André Delacourte, Jean-Pierre Vilain, Luc Buée.   

Abstract

In Alzheimer's disease, neurofibrillary degeneration results from the aggregation of abnormally phosphorylated Tau proteins into filaments and it may be related to the reactivation of mitotic mechanisms. In order to investigate the link between Tau phosphorylation and mitosis, Xenopus laevis oocytes in which most of the M-phase regulators have been discovered were used as a cell model. The human Tau isoform htau412 (2+3-10+) was microinjected into prophase I oocytes that were then stimulated by progesterone that activate cyclin-dependent kinase pathways. Hyperphosphorylation of the Tau isoform, which is characterized by a decrease of its electrophoretic mobility and its labelling by a number of phosphorylation-dependent antibodies, was observed at the time of germinal vesicle breakdown. Surprisingly, Tau immunoreactivity, considered as typical of Alzheimer's pathology (AT100 and phospho-Ser422), was observed in meiosis II. Because meiosis II is considered as a mitosis-like phase, we investigated if our observation was also relevant to a neurone-like model. Abnormal Tau phosphorylation was detected in mitotic human neuroblastoma SY5Y cells overexpressing Tau. Regarding AT100-immunoreactivity and phospho-Ser422, we suggest that phosphatase 2A inhibition and a phosphorylation combination of mitotic kinases may lead to this Alzheimer-type phosphorylation. Our results not only demonstrate the involvement of mitotic kinases in Alzheimer-type Tau phosphorylation but also indicate that Xenopus oocyte could be a useful model to identify the kinases involved in this process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12423251     DOI: 10.1046/j.1471-4159.2002.01143.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  25 in total

Review 1.  Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.

Authors:  Chinthalapally V Rao; Mudassir Farooqui; Adam S Asch; Hiroshi Y Yamada
Journal:  Cell Cycle       Date:  2018-09-20       Impact factor: 4.534

2.  Caffeine modulates tau phosphorylation and affects Akt signaling in postmitotic neurons.

Authors:  Antonio Currais; Kiyoko Kato; Leonides Canuet; Ryouhei Ishii; Toshihisa Tanaka; Masatoshi Takeda; Salvador Soriano
Journal:  J Mol Neurosci       Date:  2010-09-14       Impact factor: 3.444

Review 3.  Tau and tauopathies.

Authors:  Gloria Lee; Chad J Leugers
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

4.  Relationship of adult neurogenesis with tau phosphorylation and GSK-3β activity in subventricular zone.

Authors:  Xiao-Ping Hong; Cai-Xia Peng; Wei Wei; Qing Tian; Ying-Hua Liu; Fu-Yuan Cao; Qun Wang; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2011-02       Impact factor: 3.996

5.  Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.

Authors:  Patrice Delobel; Isabelle Lavenir; Graham Fraser; Esther Ingram; Max Holzer; Bernardino Ghetti; Maria Grazia Spillantini; R Anthony Crowther; Michel Goedert
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

Review 6.  Protein phosphorylation and APP metabolism.

Authors:  Edgar F da Cruz e Silva; Odete A B da Cruz e Silva
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

7.  Dexmedetomidine increases tau phosphorylation under normothermic conditions in vivo and in vitro.

Authors:  Robert A Whittington; László Virág; Maud Gratuze; Franck R Petry; Anastasia Noël; Isabelle Poitras; Geoffrey Truchetti; François Marcouiller; Marie-Amélie Papon; Noura El Khoury; Kevin Wong; Alexis Bretteville; Françoise Morin; Emmanuel Planel
Journal:  Neurobiol Aging       Date:  2015-05-09       Impact factor: 4.673

Review 8.  Signal transduction therapeutics: relevance for Alzheimer's disease.

Authors:  Odete A B da Cruz e Silva; Margarida Fardilha; Ana Gabriela Henriques; Sandra Rebelo; Sandra Vieira; Edgar F da Cruz e Silva
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

9.  Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1.

Authors:  Patrice Delobel; Isabelle Lavenir; Bernardino Ghetti; Max Holzer; Michel Goedert
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

10.  What Renders TAU Toxic.

Authors:  Jürgen Götz; Di Xia; Gerhard Leinenga; Yee Lian Chew; Hannah Nicholas
Journal:  Front Neurol       Date:  2013-06-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.